

**Vimta Labs Limited**

Registered Office  
142, IDA Phase II, Cherlapally  
Hyderabad-500 051, Telangana, India  
T : +91 40 2726 4141  
F : +91 40 2726 3657



Driven by Quality. Inspired by Science.

VLL\SE\030\2025-26

Date: 06.06.2025

B S E Limited, P J Towers, Dalal Street, Mumbai - 400001. Scrip Code : 524394	National Stock Exchange of India Limited, “Exchange Plaza”, Bandra, Kurla Complex, Bandra (E), Mumbai – 400051. Trading Symbol: VIMTALABS
----------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

**Sub: Re-appointment of Independent Director.**

**Ref:**

- **Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**
- **Submission of Voting Results and Scrutinizer Report of 35<sup>th</sup> Annual General Meeting (AGM) held on Friday, 06<sup>th</sup> June 2025 &**
- **Notice of the 35<sup>th</sup> Annual General Meeting (reference no. VLL/SE/17/2025-26 dated 15<sup>th</sup> May 2025)**

With reference to the subject cited above, this is to inform that the shareholders at the Annual General Meeting held today i.e., on 06<sup>th</sup> June 2025 has approved the reappointment of Dr. Yadagiri R Pendri (DIN: 01966100) as an independent director of the Company, for the second and final term of five years commencing from 10<sup>th</sup> August 2025 to 09<sup>th</sup> August 2030.

Pursuant to SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023 & Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024, a brief profile of Dr. Yadagiri R Pendri is enclosed as Annexure-I.

This is for your information and records.

Thanking you,

**For VIMTA LABS LIMITED**

**Sujani Vasireddi**  
**Company Secretary**




Encl: as above.

Page 1 of 3

**Annexure - I****RE-APPOINTMENT OF DR. YADAGIRI R PENDRI AS INDEPENDENT DIRECTOR**

<b>Particulars</b>	<b>Details</b>
Reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise;</del>	Re-appointment
Date of re-appointment & Term of re-appointment	The shareholders have approved the re-appointment on 06 <sup>th</sup> June 2025. Term of Appointment: 10 <sup>th</sup> August 2025 to 09 <sup>th</sup> August 2030, the director is not liable to retire by rotation.
Brief Profile, Key Skills., Areas of Expertise along with experience	<ul style="list-style-type: none"> <li>• Possess more than Thirty-Five years of experience in pharmaceutical research and development and has led several research programs to deliver novel drug candidates to market.</li> <li>• Founder of Escientia Lifesciences Private Limited, a contract development and manufacturing organization (CDMO), to develop and manufacture active pharmaceutical ingredients (API) to supply to global pharmaceutical and biotech companies.</li> <li>• Adept and successful at Business Management, management of company strategy including marketing, sales, trade relations, strategic partnerships, development, manufacturing, and supply.</li> <li>• Experienced in fiduciary responsibilities of Board of Directors and providing guidance to executive teams in developing compelling strategic plans and market positioning strategy for his company and their research programs.</li> <li>• Established strategic direction and drove innovation that led to timely development of multiple drug candidates.</li> <li>• Managed 200 employees at R&amp;D sites and a manufacturing site while ensuring accountability for over \$20 M turnover per year.</li> <li>• Established global academic and industrial collaborations and partnerships to drive innovation.</li> <li>• Developed and maintained relationships with strategic partners and scientific leaders to ensure timely progression of research and development activities.</li> <li>• A recognized leader in the areas of process research and development; an inventor of over 15 US patents; and author of over 35 published papers, reviews and book chapters.</li> </ul>



**Vimta Labs Limited**

Registered Office  
142, IDA Phase II, Cherlapally  
Hyderabad-500 051, Telangana, India  
T : +91 40 2726 4141  
F : +91 40 2726 3657



Driven by Quality. Inspired by Science.

Particulars	Details
	<p>Key Positions held: CEO Escientia Life Sciences, August 2005 – present CEO Escientia Life Sciences, Connecticut, USA Director Escientia Biopharma Pvt. Ltd., Hyderabad, India Director Escientia Advanced Sciences Pvt. Ltd., Visakhapatnam, India Director, Bristol-Myers Squibb &amp; Co. USA Jan 1988 – Apr 2005</p> <p>Education: Ph.D., National Chemical Laboratory, Pune, India Postdoc: UT Southwestern Medical Center, Dallas, Texas, USA</p>
Disclosure of relationships between Directors (in case of appointment of a Director)	Dr. Yadagiri R Pendri is not related to any of the Directors of the Company.
Shareholding if any in the Company	Nil
Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively.	Dr. Yadagiri R Pendri is not debarred from holding the office of a Director by virtue of any SEBI Order or any other such authority.

